- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.11. | Century Therapeutics stock downgraded by Leerink Partners on lack of catalysts | 4 | Investing.com | ||
| 13.11. | Century Therapeutics, Inc.: Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update | 156 | GlobeNewswire (Europe) | Announced iPSC derived beta islet cell program for Type 1 diabetes (T1D); Investigational New Drug (IND)-enabling studies expected to initiate by year-end 2025; IND submission planned in 2026CNTY-308... ► Artikel lesen | |
| 13.11. | Century Therapeutics unveils T1D therapy program with immune evasion tech | 5 | Investing.com | ||
| 13.11. | Century Therapeutics, Inc.: Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes | 997 | GlobeNewswire (Europe) | Allo-Evasion 5.0-engineered iPSC beta islets are designed to overcome immune rejection and provide durable glucose control without chronic immunosuppressionCompelling preclinical data demonstrate... ► Artikel lesen | |
| 13.11. | Century Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11. | Century Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| CENTURY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 29.08. | Century Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 14.08. | Century Therapeutics GAAP EPS of -$0.38 | 2 | Seeking Alpha | ||
| 14.08. | Century Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.08. | Century Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.08. | Century Therapeutics, Inc.: Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | 212 | GlobeNewswire (Europe) | Patient dosing ongoing in CALiPSO-1 trial; on track to report clinical data for CNTY-101 in patients with B-cell-mediated autoimmune diseases by year-end 2025CNTY-308, a CAR-iT cell therapy functionally... ► Artikel lesen | |
| 10.07. | Century Therapeutics files $200M mixed shelf offering | 4 | Seeking Alpha | ||
| 07.07. | Century Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 16.06. | Century Therapeutics hält jährliche Aktionärsversammlung ab | 15 | Investing.com Deutsch | ||
| 16.06. | Century Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 15.05. | Century Therapeutics, Inc.: Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | 342 | GlobeNewswire (Europe) | Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and... ► Artikel lesen | |
| 19.03. | Century Therapeutics, Inc.: Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update | 206 | GlobeNewswire (Europe) | Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell mediated autoimmune diseases and malignancies New concentrated... ► Artikel lesen | |
| 21.01. | Century Therapeutics, Inc.: Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned ... | 195 | GlobeNewswire (Europe) | - Investigator-initiated trial (IIT) to be led by pioneers of cell therapy in B-cell mediated autoimmune disease, the Schett/Mackensen group at Friedrich-Alexander University Erlangen-Nürnberg - -... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,510 | +3,96 % | Kaufempfehlung und Großauftrag: Evotec, Nordex, Desert Gold | Sind über 100 % Kursgewinn bei der Nordex-Aktie noch nicht genug? Dies glauben jedenfalls Analysten. Zudem hat der Windturbinenhersteller auch noch einen Großauftrag an Land gezogen. Geht die Rally... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 18,970 | -5,15 % | Palatin Technologies, Inc.: Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement... ► Artikel lesen | |
| VIKING THERAPEUTICS | 30,500 | +1,43 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity
Enrollment Completed Ahead of Schedule and Above Target Size, Indicating Strong Interest in... ► Artikel lesen | |
| ABIVAX | 110,00 | +0,92 % | Truist Securities startet Coverage für Abivax mit Kaufempfehlung und hohem Kursziel | ||
| GERON | 0,980 | -2,22 % | Geron Corporation Announces Executive Leadership Transitions and Appointments | FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| ASEP MEDICAL | 6,021 | -100,00 % | Asep Medical validiert seinen Sepset(ER) Diagnosetest bei Patienten in der führenden wissenschaftlichen Fachzeitschrift Nature Communications. | 27. Mai 2025 / IRW-Press / Asep Medical Holdings Inc. ("Asep Medical" oder das "Unternehmen") (CSE: ASEP) (OTCQB: SEPSF) (FWB: JJ80) freut sich
bekanntzugeben, dass seine Tochtergesellschaft... ► Artikel lesen | |
| VIDAC PHARMA | 0,526 | -0,75 % | PTA-News: Vidac Pharma Holding PLC: Bevorstehende Einbeziehung in den Freiverkehr der Börse Düsseldorf, Teilbereich Primärmarkt, und öffentliches Angebot | DJ PTA-News: Vidac Pharma Holding PLC: Bevorstehende Einbeziehung in den Freiverkehr der Börse Düsseldorf, Teilbereich Primärmarkt, und öffentliches Angebot
Unternehmensmitteilung für den Kapitalmarkt... ► Artikel lesen | |
| GALAPAGOS NV | 26,820 | 0,00 % | Gilead wants us to 'rebuild': Why Galapagos isn't allowed to go extinct after turbulent year | ||
| CELLECTAR BIOSCIENCES | 3,050 | +5,17 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom's Macroglobulinemia in 2026 Following Advice and Guidance from Scientific... ► Artikel lesen | |
| CYTOKINETICS | 58,00 | -0,85 % | Cytokinetics, Incorporated: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | ||
| CYTOMX THERAPEUTICS | 3,602 | +4,41 % | CytomX Therapeutics stock holds Overweight rating at Cantor Fitzgerald | ||
| PALISADE BIO | 2,140 | -5,52 % | Palisade Bio, Inc.: Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations | Seasoned Pharmaceutical leader bringing over 24 years of experience in clinical development across autoimmune, metabolic, cardiovascular, and gastrointestinal indications Company remains focused on... ► Artikel lesen | |
| FIBROGEN | 7,350 | -2,65 % | XFRA 1FG0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CYBIN | 5,200 | +1,96 % | Canaccord Genuity lowers Cybin stock price target to $45 on dilution | ||
| SPERO THERAPEUTICS | 1,958 | -5,18 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update | PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero... ► Artikel lesen |
Das Unternehmen CENTURY THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,33 % bei einem Aktienkurs von 0,532 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CENTURY THERAPEUTICS INC finden Sie auf Wallstreet Online.